AKUMS launches Aztreonam-Avibactam injection to combat multidrug-resistant infections

The product is manufactured at AKUMS’ state-of-the-art injectable facility in Kotdwar, Uttarakhand

AKUMS Drugs & Pharmaceuticals Limited has announced the launch of Aztreonam-Avibactam Injection, an advanced antibiotic therapy targeting multidrug-resistant gram-negative bacterial infections. 

The product is manufactured at AKUMS’ state-of-the-art injectable facility in Kotdwar, Uttarakhand. 

“The rise of antimicrobial resistance has significantly reduced the effectiveness of conventional therapies,” said Sanjeev Jain, Managing Director, AKUMS. “Aztreonam-Avibactam represents an important advancement in addressing infections caused by highly resistant pathogens, especially where timely and effective intervention is critical.”

Aztreonam-Avibactam combines aztreonam, a monobactam antibiotic effective against gram-negative bacteria, with avibactam, a beta-lactamase inhibitor that protects the antibiotic from enzymatic degradation. This dual-action mechanism enhances its efficacy against resistant strains, enabling treatment of infections that show limited or no response to existing therapies.

“Our Kotdwar facility reflects our commitment to delivering high-quality, globally compliant pharmaceutical solutions,” said Sandeep Jain, Managing Director, AKUMS. “With advanced infrastructure, specialized manufacturing environments, and robust quality systems, we ensure that complex therapies such as Aztreonam-Avibactam are developed and produced with the highest standards of safety, efficacy, and reliability.”